Skip to main content
. Author manuscript; available in PMC: 2022 Mar 1.
Published in final edited form as: Adv Ther (Weinh). 2021 Jan 20;4(3):2000243. doi: 10.1002/adtp.202000243

Figure 2: Dose Comparison Between Multiple-Dose SQ3370 and Doxorubicin Hydrochloride in Mice.

Figure 2:

C57BL/6 were treated intravenously with SQ3370 (5 doses of SQP33 protodrug following a single subcutaneous injection of SQL70 biopolymer). Animals given only Dox HCl at the 8.1 mg/kg Q4D x 3 days were used as a control. When given over 5 cycles (28.6 mg/kg QD Dox eq x 5 days), SQP33 was well tolerated at 5.9 times the dose of conventional Dox.